Ignite Creation Date:
2024-06-16 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06436040
Status:
RECRUITING
Last Update Posted:
2024-05-30
First Post:
2024-01-22
Brief Title:
Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma
Sponsor:
Tang-Du Hospital
Organization:
Tang-Du Hospital
Study Overview
Official Title:
A Mechanism Study to Investigate the Difference in Efficacy of Neoadjuvant PD-1 Blockade Combined With Chemotherapy in the Treatment of IIA-IIIB Stage Lung Squamous Cell Carcinoma
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To explore mechanisms of immunotherapy resistance and relation to changes in the TME before and after PD-1 blockade combined with chemotherapy
Detailed Description:
The biobank of thoracic surgery department of Tangdu Hospital collected pre-treatment tissues from patients during endoscopy The investigators retrospectively summarized the clinical characteristics of these patients and patients with operable locally advanced lung squamous cell carcinoma were selected and followed
The investigators plan to employ snRNA-seq and scRNA-seq respectively to profile 20 samples of paired pre-treatment and post-treatment tumors from ten patients discovery cohort to create a cell atlas for analysis and spatial transcriptomics to examine 8 samples from four patients In discovery cohort estimated 5 patients achieve major pathological response MPR and 5 patients achieve non-MPR after NICB
After analyzing the results of discovery cohort the investigators will collect frozen tissues and formalin-fixed paraffin-embedded FFPE tissue from our biobank for bulk RNA-seq analysis or immunohistochemistry IHC staining as validation cohort to further investigate the predictive value and biological significance of our markers
The investigators plan to employ snRNA-seq and scRNA-seq respectively to profile 20 samples of paired pre-treatment and post-treatment tumors from ten patients discovery cohort to create a cell atlas for analysis and spatial transcriptomics to examine 8 samples from four patients In discovery cohort estimated 5 patients achieve major pathological response MPR and 5 patients achieve non-MPR after NICB
After analyzing the results of discovery cohort the investigators will collect frozen tissues and formalin-fixed paraffin-embedded FFPE tissue from our biobank for bulk RNA-seq analysis or immunohistochemistry IHC staining as validation cohort to further investigate the predictive value and biological significance of our markers
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None